Kontafarma China Holdings Ltd ( (HK:1312) ) just unveiled an announcement.
Kontafarma China Holdings Limited has announced a board meeting scheduled for March 28, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the potential payment of a final dividend, which could impact shareholder returns and reflect the company’s financial health.
More about Kontafarma China Holdings Ltd
YTD Price Performance: 3.85%
Average Trading Volume: 1,785,833
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$150.6M
See more insights into 1312 stock on TipRanks’ Stock Analysis page.